Inhibrx Biosciences, Inc. INBX Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s other accrued liabilities?
- Inhibrx Biosciences, Inc. (INBX) reported other accrued liabilities of $693K in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s other accrued liabilities changed year-over-year?
- Inhibrx Biosciences, Inc.'s other accrued liabilities increased by 82.4% year-over-year, from $380K to $693K.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s other accrued liabilities?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s other accrued liabilities has grown at a -19.2% compound annual growth rate (CAGR), from $503K to $328K.